KCT0002938招募中未知
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study to Evaluate the Safety and Tolerability of SKL20540 in Healthy Subjects
SK Biopharmaceuticals0 个研究点目标入组 92 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- Male
入选标准
- •1.19 to 55 years of age (inclusive) who volunteer for study participation and are able to read, understand, sign, and date a written informed consent form (ICF) before study participation at screening.
- •2.Subjects must agree to use 2 highly effective methods of contraception, including at least one barrier method.
- •3.55 kg = subjects weighing < 90 kg with body mass index (BMI) between 18.0 and 27.0 kg/m2 (inclusive) at screening.
- •4.Judged to be in good health on the basis of medical history, physical examination, and routine laboratory measurements (i.e., without clinically relevant pathology).
- •5.Not clinically significant ECG or normal ECG, arterial blood pressure (100 - 140/50 - 90 mmHg), and heart rate (50 90 bpm).
- •6.Able to understand and comply with protocol requirements and instructions and likely to complete the study as planned.
- •7.Non-smokers (subjects who have stopped smoking at least 6 months before screening and showed a negative result in cotinine urine test at screening are eligible or who have not smoked)
排除标准
- •1.History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
- •2.Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with pharmacokinetics of the trial medication (except appendectomy and simple hernia repair).
- •3.Regular treatment with prescription medications. Subjects should have ended any prescription medications at least 14 days before the first dosing of the study drug. Potential subjects should only stop any prescribed medication at the direction of a physician.
- •4.Regular treatment with nonprescription medications. Subjects should have ended any nonprescription medications at least 14 days before the first dosing of the study drug. Potential subjects should consult a physician before stopping any regular treatment with nonprescription medication.
- •5.Consumption of herbal medications, dietary supplements, and specific fruit products. Subjects should have stopped consumption of herbal medications or dietary supplements (e.g., St. John’s Wort, ginkgo biloba, and garlic supplements), vitamins, and grapefruit or grapefruit juice, or Seville oranges at least 14 days before the first dosing of study drug.
- •6.History of drug or alcohol abuse or addiction within 2 years before the start of study drug dosing, or a positive test for alcohol or drugs of abuse, such as cotinine, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, or opioids at screening.
- •7.Regular consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 pint [473 mL] of beer or lager, 1 glass [125 mL] of wine, 25 mL shot of 40% spirit) before screening. Subjects may not consume any alcohol from 72 hours before the first dosing of study drug through the completion of the study (last visit).
- •8.Consumption of an average of more than 5 servings (8 ounces per serving) per day of coffee, cola, or other caffeinated beverage before screening. Subjects may not consume any caffeinated beverages from 48 hours prior to dosing until the collection of the last PK sample.
- •9.Participation in a clinical study involving administration of either an investigational or a marketed drug within 3 months before screening.
- •10.Blood donation or a significant loss of blood within 60 days of the start of study drug dosing or donation of more than 1 unit of plasma within 7 days before screening.
- •11.Positive result at screening for any of the following infectious disease tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus antigen, antibody (HIV Ag, Ab).
- •12.Illness within 5 days before the start of study drug dosing (illness” is defined as an acute [serious or non-serious] condition [e.g., the flu or the common cold]).
- •13.Subjects with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption.
- •14.Agree not to donate sperm during the study and for at least 100 days after the last dose of the study medication.
- •15.History of relevant allergy/hypersensitivity (including allergy to aspirin, antibiotics, the trial medication or its excipients)
- •16.Subject is at imminent risk of suicide (positive response to question 4 or 5 on the C-SSRS (Columbia-Suicide Severity Rating Scale) or had a suicide attempt within 6 months prior to the screening vi
研究者
相似试验
终止
Unknown
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of an Orally Administered Single Dose of JBPOS0501 in Healthy VolunteersDiseases of the nervous systemKCT0008425Bio-Pharm Solutions56
进行中（未招募）
1 期
A Pneumococcal Vaccine Study A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorHealthy volunteers (toddlers), Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorMedDRA version: 20.0Level: LLTClassification code 10078416Term: Invasive bacterial infectionSystem Organ Class: 100000004862EUCTR2019-004503-12-Outside-EU/EEAAstellas Pharma Global Development Inc.
招募中
不适用
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of Getagozumab in Healthy VolunteersACTRN12618000121268Gmax Biopharm Australia Pty Ltd.32
已完成
不适用
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteersdisorder with hyperglycemia10018424diabetes mellitusNL-OMON31095ISIS Pharmaceuticals56
已完成
不适用
A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusioTraumatic brain injuryInjury, Occupational Diseases, PoisoningISRCTN67656669euren Pharmaceuticals (New Zealand)35